|
[Related PubMed/MEDLINE]
Total Number of Papers: 6440
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: GLP-1 |
| Long Form |
: glucagon-like peptide-1 |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
(EX-4)2-Fc, an effective long-acting GLP-1 receptor agonist, reduces obesity-related inflammation by inhibiting leptin expression. |
DIO, MAPK, NF-kappaB, T2D |
| 2 |
2020 |
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). |
ADA, CKD, CVD, EASD, HHF, MACE, SGLT2 |
| 3 |
2020 |
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). |
ADA, CKD, CVD, EASD, HHF, MACE, SGLT2 |
| 4 |
2020 |
A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity. |
BMI, OGTT |
| 5 |
2020 |
A Comparison of Gastric and Jejunal Feeding in Hypercatabolism Associated With Hypothalamic AMPK-Autophagy-POMC in Endotoxemic Rats. |
AMPK, EN, GF, GHS-R1alpha, JF, LPS, POMC |
| 6 |
2020 |
A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice. |
AD, GCG, LTP, Oxm, T2DM |
| 7 |
2020 |
A free-energy landscape for the glucagon-like peptide 1 receptor GLP1R. |
GPCRs |
| 8 |
2020 |
A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine. |
DM, GMS, HG, L group, LA, NIA, NIT, SDs |
| 9 |
2020 |
A GLP-2 Analogue Protects SH-SY5Y and Neuro-2a Cells Against Mitochondrial Damage, Autophagy Impairments and Apoptosis in a Parkinson Model. |
GLP-2, PD, TEM |
| 10 |
2020 |
A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer? |
NAFLD, SGLT2, T2D |
| 11 |
2020 |
A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice. |
DIO, GCG, NASH, OXM, PEG |
| 12 |
2020 |
A novel mouse model of glucagon-like peptide-1 receptor expression: A look at the brain. |
CNS, mApple |
| 13 |
2020 |
A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential. |
GIP, OGTT |
| 14 |
2020 |
A Physiologically-Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP-1 and GIP and the DPP4 Inhibitor Sitagliptin. |
DPP4, GIP, NEP, PB |
| 15 |
2020 |
A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery. |
--- |
| 16 |
2020 |
A Protein/Lipid Preload Attenuates Glucose-Induced Endothelial Dysfunction in Individuals with Abnormal Glucose Tolerance. |
GIP, IGT, OGTTs, RHI, T2D |
| 17 |
2020 |
A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes. |
GIP |
| 18 |
2020 |
A Review of the Renoprotective Effects of Novel Antidiabetic Agents. |
DPP-4, SGLT2 |
| 19 |
2020 |
A systematic review and meta-analysis of medium-chain triglycerides effects on acute satiety and food intake. |
GIP, LCT, MCT, PP, PYY |
| 20 |
2020 |
Abdominal aortic aneurysm: a review on the role of oral antidiabetic drugs. |
AAA, DPP-4, SGLT2, SU, TZD |
| 21 |
2020 |
Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats. |
--- |
| 22 |
2020 |
Activation of the GLP-1 receptor by a non-peptidic agonist. |
--- |
| 23 |
2020 |
Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction. |
AMPK, DPP-4, SIRT1, TRPV4 |
| 24 |
2020 |
Acute effects of an isocaloric macronutrient-matched breakfast meal containing almonds on glycemic, hormonal, and appetite responses in men with type 2 diabetes: a randomized crossover study. |
T2D |
| 25 |
2020 |
Acute effects of sitagliptin on progenitor cells and soluble mediators in newly diagnosed type 2 diabetes. |
EPCs, ET-1, NO, SDF-1alpha |
| 26 |
2020 |
Acute exposure to a hot ambient temperature reduces energy intake but does not affect gut hormones in men during rest. |
PYY |
| 27 |
2020 |
Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes. |
DPP4, SGLT2 |
| 28 |
2020 |
Albumin-binding domain extends half-life of glucagon-like peptide-1. |
ABD, HSA, T2DM |
| 29 |
2020 |
Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. |
AUD, Ex-4 |
| 30 |
2020 |
Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. |
--- |
| 31 |
2020 |
Alterations in Enteroendocrine Hormones After Total Pancreatectomy With Islet Autotransplantation. |
PP, PYY, TPIAT |
| 32 |
2020 |
Alterations in pancreatic islet cell function in response to small bowel resection. |
SBR |
| 33 |
2020 |
Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice. |
ACC, AMPK, FSI |
| 34 |
2020 |
Amino Acids in Health and Endocrine Function. |
IGF-1 |
| 35 |
2020 |
An Almond-Based Low Carbohydrate Diet Improves Depression and Glycometabolism in Patients with Type 2 Diabetes through Modulating Gut Microbiota and GLP-1: A Randomized Controlled Trial. |
a-LCD, LCD, LFD |
| 36 |
2020 |
An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice. |
OHP2 |
| 37 |
2020 |
Anagliptin stimulates osteoblastic cell differentiation and mineralization. |
ALP, OCN, OPN |
| 38 |
2020 |
Anagliptin, a dipeptidyl peptidase-4 inhibitor, improved bladder function and hemodynamics in rats with bilateral internal iliac artery ligation. |
Ana, DPP-4, ICIs, LIG |
| 39 |
2020 |
Antagonistic interaction between central glucagon-like Peptide-1 and oxytocin on diet-induced obesity mice. |
DIO, OXT |
| 40 |
2020 |
Anti-hyperglycemic activity of myricetin, through inhibition of DPP-4 and enhanced GLP-1 levels, is attenuated by co-ingestion with lectin-rich protein. |
DC, DPP-4, HP, Myr, NLRP3, STZ |
| 41 |
2020 |
Antidiabetic drug therapy alleviates type 1 diabetes in mice by promoting pancreatic alpha-cell transdifferentiation. |
GIP, SGLT2 |
| 42 |
2020 |
Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. |
CIs, DPP4, NAFLD, SGLT2, SMDs, WMDs |
| 43 |
2020 |
Antidiabetic effects of selenium-enriched Bifidobacterium longum DD98 in type 2 diabetes model of mice. |
FBG, Se-B. longum DD98, STZ |
| 44 |
2020 |
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. |
HCC, NAFLD, NASH, SGLT2, T2D |
| 45 |
2020 |
Appetite control: hormones or diet strategies? |
PYY |
| 46 |
2020 |
Appetite-regulating hormones and anthropometric indicators of infants according to the type of feeding. |
FBF, HMS, PBF |
| 47 |
2020 |
Appetite-Regulating Hormones in Human Milk: A Plausible Biological Factor for Obesity Risk Reduction? |
PYY |
| 48 |
2020 |
Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced. |
--- |
| 49 |
2020 |
Assessing the effect of starch digestion characteristics on ileal brake activation in broiler chickens. |
PYY, SCFA, WS |
| 50 |
2020 |
Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. |
HRs, SGLT2 |
| 51 |
2020 |
Assessment of antidiabetic potential and phytochemical profiling of Rhazya stricta root extracts. |
DPP-IV |
| 52 |
2020 |
Assessment of Second-Generation Diabetes Medication Initiation Among Medicare Enrollees From 2007 to 2015. |
DPP-4, SGLT2 |
| 53 |
2020 |
Association between allelic variants in the glucagon-like peptide 1 and cholecystokinin receptor genes with gastric emptying and glucose tolerance. |
GE, SNPs |
| 54 |
2020 |
Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal. |
DPP-4, GLP-1R |
| 55 |
2020 |
Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects. |
CA7S, GI, TGR5 |
| 56 |
2020 |
Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: Involvement of Oxidative Stress. |
--- |
| 57 |
2020 |
Bifidobacterium from breastfed infant faeces prevent high-fat-diet-induced glucose tolerance impairment, mediated by the modulation of glucose intake and the incretin hormone secretion axis. |
HFD |
| 58 |
2020 |
Bile acid treatment and FXR agonism lower postprandial lipemia in mice. |
DCA, FXR, TA, TGR5 |
| 59 |
2020 |
Binge-like palatable food intake in rats reduces preproglucagon in the nucleus tractus solitarius. |
NTS, PPG |
| 60 |
2020 |
Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process. |
--- |
| 61 |
2020 |
Brain insulin resistance: role in neurodegenerative disease and potential for targeting. |
GIP |
| 62 |
2020 |
Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. |
AD, BBB, CNS, GIP, IRAs, PD |
| 63 |
2020 |
Butyric acid normalizes hyperglycemia caused by the tacrolimus-induced gut microbiota. |
PYY |
| 64 |
2020 |
Cacao polyphenols regulate the circadian clock gene expression and through glucagon-like peptide-1 secretion. |
CLPr |
| 65 |
2020 |
Caloric restriction alters the hormonal profile and testicular metabolome, resulting in alterations of sperm head morphology. |
CR |
| 66 |
2020 |
Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality? |
--- |
| 67 |
2020 |
Capsaicin improves glucose homeostasis by enhancing glucagon-like peptide-1 secretion through the regulation of bile acid metabolism via the remodeling of the gut microbiota in male mice. |
BA, CAP, HFD, LCA, TGR5 |
| 68 |
2020 |
Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-alpha. |
caECs, CASMCs, MTPalpha, NEP-generated, sAC-dependent |
| 69 |
2020 |
Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. |
CKD, SGLT2, T2D |
| 70 |
2020 |
Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. |
GLP-1RAs, T2DM |
| 71 |
2020 |
CCK-1 and CCK-2 receptor agonism do not stimulate GLP-1 and neurotensin secretion in the isolated perfused rat small intestine or GLP-1 and PYY secretion in the rat colon. |
CCK, GIP, PYY, VIP |
| 72 |
2020 |
Cerebral effects of GLP-1 receptor blockade before and after Roux-en-Y Gastric Bypass in obese women: a proof-of-concept resting-state fMRI study. |
RYGB |
| 73 |
2020 |
Changes in incidence of severe hypoglycaemia in people with type 2 diabetes from 2006 to 2016: analysis based on health insurance data in Germany considering the anti-hyperglycaemic medication. |
ATC, DPP-4, OR, SGLT2 |
| 74 |
2020 |
Childhood trauma and glucose metabolism in patients with first-episode psychosis. |
BMI, CT, FEP, GIP, PAI-1, SLEs |
| 75 |
2020 |
Chitooligosaccharides Modulate Glucose-Lipid Metabolism by Suppressing SMYD3 Pathways and Regulating Gut Microflora. |
COS, CYP7A1, HMGCR, SMYD3, T2DM |
| 76 |
2020 |
Choice of Lipid Emulsion Determines Inflammation of the Gut-Liver Axis, Incretin Profile, and Insulin Signaling in a Murine Model of Total Parenteral Nutrition. |
JVC, TPN |
| 77 |
2020 |
Chronic high fat diet impairs glucagon like peptide-1 sensitivity in vagal afferents. |
Ex-4, HFF, LFF, NTS |
| 78 |
2020 |
Chronic n-3 fatty acid intake enhances insulin response to oral glucose and elevates GLP-1 in high-fat diet-fed obese mice. |
cHF, OGTT, PUFA |
| 79 |
2020 |
Circadian GLP-1 Secretion in Mice is Dependent on the Intestinal Microbiome for Maintenance of Diurnal Metabolic Homeostasis. |
--- |
| 80 |
2020 |
Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. |
UKELD |
| 81 |
2020 |
Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. |
AGEs, BMI, i.v, OGTT, sRAGE |
| 82 |
2020 |
Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy. |
GIP, PYY, T2D |
| 83 |
2020 |
Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice. |
DIO |
| 84 |
2020 |
Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes. |
CV, SGLT2 |
| 85 |
2020 |
Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? |
CKD, NAFLD, NASH, SGLT2, SKLT, T2D |
| 86 |
2020 |
Comparable Postprandial Amino Acid and Gastrointestinal Hormone Responses to Beef Steak Cooked Using Different Methods: A Randomised Crossover Trial. |
aa, GI, GIP, PF, SV, UPLC |
| 87 |
2020 |
Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data. |
--- |
| 88 |
2020 |
Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: A meta-analysis. |
alpha-GIs, DPP-4, HOMA-beta, PIR, SGLT2 |
| 89 |
2020 |
Conservation of glucagon like peptide-1 level with liraglutide and linagilptin protects the kidney against angiotensin II-induced tissue fibrosis in rats. |
Ang II |
| 90 |
2020 |
Consuming decaffeinated coffee with milk and sugar added before a high-glycaemic index meal improves postprandial glycaemic and insulinaemic responses in healthy adults. |
GI |
| 91 |
2020 |
Controlled Release of Pyrimidine Compound Using Polymeric Coated ZIF-8 Metal-Organic Framework as Glucagon-Like Peptide-1 Receptor Agonist Carrier. |
MOFs |
| 92 |
2020 |
Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus. |
AEs, BMI, NHS, QALYs, SA, T2DM, UKPDS |
| 93 |
2020 |
Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review. |
ACEI, ARBs, NSAIDs, SYRCLE |
| 94 |
2020 |
Cyclocarya paliurus polysaccharides alleviate type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids. |
CCPP, PYY, SCFAs, T2DM |
| 95 |
2020 |
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice. |
SGLT2 |
| 96 |
2020 |
Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis Metalloprotease GelE. |
--- |
| 97 |
2020 |
Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes. |
CI, DPP4, IRR |
| 98 |
2020 |
Diabetes: From Research to Clinical Practice. |
CGM, CSII, SGLT2 |
| 99 |
2020 |
Dietary Cyanidin-3-Glucoside Attenuates High-Fat-Diet-Induced Body-Weight Gain and Impairment of Glucose Tolerance in Mice via Effects on the Hepatic Hormone FGF21. |
ABs, Cy3G, Exp, FGF21, HFD, LFD |
| 100 |
2020 |
Dietary macronutrient regulation of acyl and desacyl ghrelin concentrations in children with Prader-Willi syndrome (PWS). |
AG, DAG, HC, HP-LC, HP-LF, PWS, PYY |
|
A Search Service for Abbreviation / Long Form
